Trial Profile
An Open-Label Study to Evaluate the Penetration of Doripenem in Cerebrospinal Fluid After Doripenem Administration in Pediatric Subjects Less Than 1 Year Chronological Age.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 13 Oct 2014
Price :
$35
*
At a glance
- Drugs Doripenem (Primary)
- Indications Bacterial infections; CNS infections
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 27 Dec 2012 Planned End Date changed from 1 May 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 28 Jul 2012 New source identified and integrated (European Clinical Trials Database record EudraCT2011-001114-33).
- 29 May 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.